PREVENT: Eculizumab May Lower Relapse Risk in NMOSD PREVENT: Eculizumab May Lower Relapse Risk in NMOSD

Use of eculizumab resulted in significantly greater relapse reduction over placebo in patients with neuromyelitis optica spectrum disorder (NMSOD), new findings from the phase 3 PREVENT trial show.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news